Biosensors gets complementary imaging tech with Spectrum buy
This article was originally published in Clinica
Singapore-based Biosensors International has agreed to acquire functional imaging specialist Spectrum Dynamics for $51 million plus milestones, giving it a complementary offering to its interventional cardiology business. Biosensors claims to be the world’s number-four cardiac stent company, offering both drug-eluting and bare metal stents, as well as balloon dilatation catheters. The firm also has a critical care division including vascular catheters and pressure monitoring kits.